The Sudeep Pharma IPO, which has a price range of ₹563-593, began on November 21 and ends on November 25. On the first day, it had a subscription status of 1.42x and was fully subscribed. Strong market interest is indicated by the predicted listing price of ₹714. Today's IPO GMP for Sudeep Pharma is ₹121.
Sudeep Pharma's initial public offering (IPO), which began on Friday, November 21, is scheduled to end on Tuesday, November 25. On Friday, the first day of the share sale, Sudeep Pharma's IPO was completely subscribed. On November 21, the first day of bidding, Sudeep Pharma's IPO subscription status was 1.42 times.The pricing range for Sudeep Pharma's initial public offering (IPO) is ₹563–593 per equity share. Sudeep Pharma has given qualified institutional buyers (QIB) up to 50% of the shares in the IPO, non-institutional investors (NII) at least 15%, and retail investors at least 35%.
On Wednesday, November 26, the Sudeep Pharma IPO's preliminary basis for share allocation will be decided, and refunds will be handled on Thursday, November 27. On the same day as the refunds, shares will be credited to the allottees' demat accounts. On Friday, November 28, the share price of Sudeep Pharma is anticipated to make its debut on the BSE and NSE.
On Wednesday, November 26, the Sudeep Pharma IPO's preliminary basis for share allocation will be decided, and refunds will be handled on Thursday, November 27. On the same day as the refunds, shares will be credited to the allottees' demat accounts. On Friday, November 28, the share price of Sudeep Pharma is anticipated to make its debut on the BSE and NSE.
Due to its manufacturing capability, Gujarat-based Sudeep Pharma is one of the top manufacturers of food-grade iron phosphate used in clinical nutrition, baby nutrition, and the food and beverage industries. The company focuses on minerals like calcium, iron, magnesium, zinc, potassium, and salt and operates six production facilities with a combined capacity of 50,000 MT.
Today's IPO GMP for Sudeep Pharma
Today's IPO GMP for Sudeep Pharma is ₹121. The expected listing price of Sudeep Pharma shares was ₹714 per share, which is 20.40% more than the IPO price of ₹593, taking into account the upper end of the IPO pricing band and the existing premium in the grey market.
Today's IPO GMP for Sudeep Pharma
Today's IPO GMP for Sudeep Pharma is ₹121. The expected listing price of Sudeep Pharma shares was ₹714 per share, which is 20.40% more than the IPO price of ₹593, taking into account the upper end of the IPO pricing band and the existing premium in the grey market.
The IPO GMP is on an upward trajectory today and is expected to have a strong listing based on the grey market patterns seen over the last eight sessions. According to experts, the highest reported GMP is ₹130, while the lowest is ₹0.00.
Status of Sudeep Pharma's IPO Subscription
On day one, Sudeep Pharma's IPO subscription status was 1.42x. Qualified Institutional Buyers (QIBs) received 3.00x bids, the NII portion was booked 48%, and the retail portion was subscribed 1.50x.
According to BSE data, at 17:00 IST, the company got bids for 1,50,09,425 shares out of 1,05,64,926 shares on sale.
Status of Sudeep Pharma's IPO Subscription
On day one, Sudeep Pharma's IPO subscription status was 1.42x. Qualified Institutional Buyers (QIBs) received 3.00x bids, the NII portion was booked 48%, and the retail portion was subscribed 1.50x.
According to BSE data, at 17:00 IST, the company got bids for 1,50,09,425 shares out of 1,05,64,926 shares on sale.
Sudeep Pharma IPO Review According to Swastika Investmart, the company is performing well, with rising revenues, higher EBITDA margins, and a notable FY25 RONW of 27.88%. Serving a long list of prestigious international customers, it serves as a vital partner for pharmaceutical-grade chemicals.
At a P/E ratio of 45–48x, the issue is considered "aggressively priced" and accurately reflects its current consistent profitability. There is no chance of short-term increases or instant listing gains due to this high valuation. Only with a holding duration of two to five years are aggressive investors urged to apply, according to the brokerage.
At a P/E ratio of 45–48x, the issue is considered "aggressively priced" and accurately reflects its current consistent profitability. There is no chance of short-term increases or instant listing gains due to this high valuation. Only with a holding duration of two to five years are aggressive investors urged to apply, according to the brokerage.
According to Geojit Investments, SPL is selling at a P/E ratio of 48x based on FY25 diluted earnings at the maximum price point of ₹593, which appears to be a fair valuation. Strong operational results, the acquisition of NSS, which strengthens the company's position in the European market for infant feeding and formulations, and its planned entry into the quickly expanding battery-grade minerals industry all support the company's long-term growth.
"SPL offers a compelling long-term story when combined with a solid balance sheet, a committed R&D focus, and ongoing product innovation. For investors with a medium- to long-term investment view, we thus give them a SUBSCRIBE rating," the brokerage stated.
"SPL offers a compelling long-term story when combined with a solid balance sheet, a committed R&D focus, and ongoing product innovation. For investors with a medium- to long-term investment view, we thus give them a SUBSCRIBE rating," the brokerage stated.
Details of Sudeep Pharma's IPO
A new issue of equity shares priced at ₹95 crore and a selling offer of roughly 1.35 crore equity shares, totaling ₹800 crore from the promoters, make up the Sudeep Pharma IPO.
The ₹75.81 crore collected from the new issue would be used for both general corporate purposes and capital expenditures relating to the procurement of machinery for its production facility at Nandesari Facility 1 in Gujarat.
The merchant bankers for the Sudeep Pharma IPO are ICICI Securities and IIFL Capital Services. The registrar for this issuance is MUFG Intime India Pvt. Ltd.
A new issue of equity shares priced at ₹95 crore and a selling offer of roughly 1.35 crore equity shares, totaling ₹800 crore from the promoters, make up the Sudeep Pharma IPO.
The ₹75.81 crore collected from the new issue would be used for both general corporate purposes and capital expenditures relating to the procurement of machinery for its production facility at Nandesari Facility 1 in Gujarat.
The merchant bankers for the Sudeep Pharma IPO are ICICI Securities and IIFL Capital Services. The registrar for this issuance is MUFG Intime India Pvt. Ltd.
0 Comments